1531-8249/asset/olbannerleft.gif?v=1&s=d36d5ebb3caa1b29d7f078a97c52973b0963daf2)
1531-8249/asset/olbannerright.gif?v=1&s=078041b213f6959d63575a593f880457c45116f0)
Original Article
Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect
Article first published online: 13 SEP 2010
DOI: 10.1002/ana.22093
Copyright © 2010 American Neurological Association
Additional Information
How to Cite
Pioro, E. P., Brooks, B. R., Cummings, J., Schiffer, R., Thisted, R. A., Wynn, D., Hepner, A. and Kaye, R. (2010), Dextromethorphan Plus Ultra Low-Dose Quinidine Reduces Pseudobulbar Affect. Ann Neurol., 68: 693–702. doi: 10.1002/ana.22093
Publication History
- Issue published online: 28 OCT 2010
- Article first published online: 13 SEP 2010
- Manuscript Accepted: 20 MAY 2010
- Manuscript Revised: 30 APR 2010
- Manuscript Received: 24 FEB 2010
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, Diagnosis and management of progressive supranuclear palsy, Neurodegenerative Disease Management, 2013, 3, 1, 81
- 2, , , Multidisciplinary clinics: optimizing treatment for patients with amyotrophic lateral sclerosis, Neurodegenerative Disease Management, 2013, 3, 2, 157
- 3, , A Naturalistic On-Off-On Trial of Dextromethorphan/Quinidine for Agitation Associated with Cerebellar Injury, Psychosomatics, 2012, 53, 5, 470
- 4, , , , A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers, Clinical Drug Investigation, 2012, 32, 8, e1
- 5, , , , A Study of Potential Pharmacokinetic and Pharmacodynamic Interactions between Dextromethorphan/Quinidine and Memantine in Healthy Volunteers, Clinical Drug Investigation, 2012, 32, 8, e1
- 6, An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan, Medical Hypotheses, 2012, 78, 6, 693
- 7, Antipsychotics and Dementia: A Time for Restraint?, Journal of the American Medical Directors Association, 2012, 13, 9, 761
- 8, , , , Current Pharmacologic Management in Selected Neuromuscular Diseases, Physical Medicine and Rehabilitation Clinics of North America, 2012, 23, 4, 801
- 9
- 10, , , , Efficacy and Safety of Dextromethorphan/Quinidine at Two Dosage Levels for Diabetic Neuropathic Pain: A Double-Blind, Placebo-Controlled, Multicenter Study, Pain Medicine, 2012, 13, 2Direct Link:
- You have free access to this content11, , , , , , , , , , , , , , , EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force, European Journal of Neurology, 2012, 19, 3Direct Link:
- 12, , , , , , , Novel NMDA receptor modulators: an update, Expert Opinion on Therapeutic Patents, 2012, 22, 11, 1337
- 13, , , Pseudobulbar Affect: Burden of Illness in the USA, Advances in Therapy, 2012, 29, 9, 775
- 14, , , Randomized Open-Label Drug-Drug Interaction Trial of Dextromethorphan/Quinidine and Paroxetine in Healthy Volunteers, Clinical Drug Investigation, 2012, 32, 3, 157
- 15
- 16, , A worldwide yearly survey of new data in adverse drug reactions and interactions, 2012,
- 17
- 18
- 19
- 20, , New considerations in the design of clinical trials for amyotrophic lateral sclerosis, Clinical Investigation, 2011, 1, 10, 1375
- 21, , , , Pseudobulbar affect: an under-recognized and under-treated neurological disorder, Advances in Therapy, 2011, 28, 7, 586
- 22, , , Pseudobulbar affect: the spectrum of clinical presentations, etiologies and treatments, Expert Review of Neurotherapeutics, 2011, 11, 7, 1077
- 23
- 24, , Cognitive Dysfunction in Multiple Sclerosis,Direct Link: